Diabetes Treatment Adlyxin Will No Longer Be Available in the US

Publish Date

February 6, 2023

Adlyxin is a glucagon-like peptide-1 receptor agonist. Credit: Getty Images.

Adlyxin (lixisenatide) will no longer be available in the US, according to Sanofi.

The glucagon-like peptide-1 (GLP-1) receptor agonist, which gained approval from the Food and Drug Administration (FDA) in 2016, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

A recent posting on the FDA’s Drug Shortages tracker indicates that the product has been discontinued.

A list of alternative treatment options is available here. Therapies that fall into the same pharmacological class and are indicated for diabetes treatment include Bydureon Bcise (exenatide extended-release for subcutaneous [SC] injection), Byetta (exenatide for SC injection), Ozempic (semaglutide for SC injection), Rybelsus (semaglutide tablets), Trulicity (dulaglutide for SC injection), Victoza (liraglutide for SC injection).

References

Lixisenatide (Adlyxin) Injection. FDA Drug Shortages. Accessed February 6, 2023. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lixisenatide+%28ADLYXIN%29+Injection&st=d&tab=tabs-4&panels=0#.

This article originally appeared on MPR